|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| REVENUES | |||||
| License and Contract | |||||
| Product revenue, net | |||||
| Total Revenues | |||||
| OPERATING EXPENSES | |||||
| Cost of products sold | |||||
| Cost of products sold | |||||
| Research and development | |||||
| Loss (Gain) on sale of Vyleesi | |||||
| General and administrative | |||||
| Gain on sale of Vyleesi | |||||
| Gain on purchase commitment | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| OTHER INCOME (EXPENSE) | |||||
| Investment income | |||||
| Foreign currency gain (loss) | |||||
| Foreign currency transaction loss | |||||
| Offering expenses | |||||
| Change in fair value of warrant liabilities | |||||
| Interest expense | |||||
| Total other income, net | |||||
| Loss before income taxes | |||||
| Income tax benefit | |||||
| NET LOSS | |||||
| Basic net loss per common share | |||||
| Diluted net loss per common share | |||||
| Weighted average number of common shares outstanding used in computing basic net loss per common share | |||||
| Weighted average number of common shares outstanding used in computing diluted net loss per common share | |||||
Loading...